Huntington disease (HD) is a dominantly inherited neurodegenerative disease characterized by involuntary abnormal movements, cognitive and psychiatric symptoms. Evidence suggests that energy deficit plays a critical role in the disease pathophysiology. There is however a lack of robust biomarkers for testing therapeutic strategies targeting brain energy metabolism. This study aims to measure dynamic parameters of brain energy metabolism and identify novel functional biomarkers of for use in therapeutic trials in HD. This study showed altered creatine kinase rate in patients with HD as well as altered diffusion rates of several metabolites in the corpus callosum of patients with HD.